Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, has filed its 2024 Universal Registration Document and Annual Report for the year ended December 31, 2024, with relevant regulatory authorities in France and the United States, highlighting its focus on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other unmet medical needs [1][9]. Company Overview - Inventiva specializes in the development of oral small molecule therapies targeting MASH and other diseases with significant unmet medical needs [3]. - The company is currently conducting the NATiV3 pivotal Phase 3 clinical trial for lanifibranor, a novel pan-PPAR agonist aimed at treating adult patients with MASH [3]. - Inventiva has a scientific team of approximately 90 professionals with expertise in various fields, including biology, medicinal chemistry, and clinical development [4]. Financial Reporting - The 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F are accessible on the company's website and the websites of the French Autorité des Marchés Financiers and the U.S. Securities and Exchange Commission [2][9]. - The filings include management reports and annual financial reports, which provide insights into the company's performance and future outlook [1].
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F